WTA introduces gene testing for all players on women's tennis tour

The Womens Tennis Association is introducing one-off mandatory gene testing for all players effective from Tuesday a requirement to compete at the 2028 Los Angeles Olympics.

The WTA updated its womens eligibility policy to include gender screening based on biological sex this week to preserve the integrity of womens professional tennis and maintain fair competition conditions for all players.

The new policy takes the organization in line with the eligibility policy introduced by the International Olympic Committee in March to align with U.S. President Donald Trumps executive order on sports ahead of the 2028 Games.

IN CASE YOU MISSED IT | Linda Noskova recovers after blown match points to win Wimbledon

The WTA is complying with what is effectively an order from the IOC that Olympic sports bodies are following, though it remained unclear how many, if any, transgender women are competing at Games level.

Players are to be tested for the SRY gene, a segment of DNA typically found on the Y chromosome that initiates male sex development in utero and indicates the presence of testes.

In this policy, biological male means an individual who, regardless of their legal sex or gender identity, has an SRY gene and therefore has or previously had testes or streak testes; and biological female means an individual who, regardless of their legal sex or gender identity, has no SRY gene and therefore has or previously had ovaries or streak ovaries.

IN CASE YOU MISSED IT | Serena Williams loses in opening round at Wimbledon

The WTA said the policy distinguishes between biological sex and gender identity, and that there is no intent to disrespect or question the gender identity or the dignity of any person.

The mandatory gender screening already conducted by the governing bodies of track and field, skiing and boxing has been criticized by human rights experts and activist groups.